Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Delirium in Older Persons
NEJM 354:1157-1165, Inouye,S.K., 2006
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Reversible Dementia with Parkinsonian Features Associated with Budesonide Use
Neurol 67:723, Proda,C.I.,et al, 2006
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Recombinant Interferon-a-induced Chorea and Frontal Subcortical Dementia
Neurol 58:328-330, Moulignier,A.,et al, 2002
Drug-Induced Pisa Syndrome (Pleurothotomus)
CNS Drugs 10:166-174, Suzuki, T. & Matsuzaka, H., 2002
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Ginkgo Biloba for Dementia
The Medical Letter 40:63-64, , 1998
Metrifonate Benefits Cognitive, Behvioral, and Global Function in Patients with Alzheimer's Disease
Neurol 50:1222-1230, 12031998., Morris,J.C.,et al, 1998
Metrifonate Treatment of the Cognitive Deficits of Alzheimer's Disease
Neurol 50:1214-1221, 12031998., Cummings,J.L.,et al, 1998
Near-Fatal Heat Stroke During the 1995 Heat Wave in Chicago
Ann Int Med 129:173-181, Damatte,J.E.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
Clinical Experience with Donepezil Hydrochloride:A Case Study Perspective
Advan Therapy 14:305-311, Geldmacher,D.S., 1997
Valproic Acid Hepatic Fatalities. III. U. S. Experience Since 1986
Neurol 46:465-469, Bryant,A.E.&Dreifuss,F., 1996
Tacrine
Lancet 345:625-630, Davis,K.L.&Powchik,P., 1995
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Effectiveness & Safety of Velnacrine for Treatment of Alzheimer's Disease:A Double Blind, Placebo-Controlled Study
Arch Int Med 155:1766-1772, Antuono,P.G.,et al, 1995
The Eosinophilia-Myalgia Syndrome:Status of 205 Patients and Results of Treatment 2 Years After Onset
Ann Int Med 122:851-855, Hertzman,P.A.,et al, 1995
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
Tacrine (tetrahydroaminoacridine; THA) and Lecithin in Senile Dememtia of the Alzheimer Type:A Multicentre Trial
BMJ 300:495-499, Chatellier,G.,et al, 1990
A Functional Psychosis Precipitated by Quinidine
Med J Aust 153:47-49, Johnson,A.G., 1990
Geriatrics:Sleep Disorders and Aging
NEJM 323:520-526, Prinz,P.N.,et al, 1990
A Creutzfeldt-Jakob Like Syndrome Due to Lithium Toxicity
JNNP 51:120-123, Smith,S.J.M.&Kocen,R.S., 1988